Enanta Pharmaceuticals, Inc. (ENTA) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Watertown, MA, アメリカ. 現CEOは Jay R. Luly.
ENTA を有する IPO日 2013-03-21, 131 名の正社員, に上場 NASDAQ Global Select, 時価総額 $339.66M.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
